Main content

Pfizer, one of the world’s premier biopharmaceutical companies, has made the decision to end their neuroscience discovery program into Alzheimer’s disease and Parkinson’s disease, resulting in the loss of around 300 jobs.

Following a comprehensive review of their research efforts, Pfizer have made the decision to relocate the funding to areas where they already have strong scientific leadership.

In a statement to National Public Radio (NPR) a spokesperson for Pfizer said, "Any decision impacting colleagues is difficult; however, we believe this will best position the company to bring meaningful new therapies to market, and will bring the most value for shareholders and patients."

This news will come as an enormous disappointment to people living with Alzheimer’s disease all over the world. There are 90,000 people in Scotland living with dementia right now and that number is set to rise. Here at Alzheimer Scotland we continue to support dementia research, looking not only into treatments and cures, but also into improving the care provided for people living with dementia right now.

For more information on our research involvements go to